Anne Lazareth
YOU?
Author Swipe
View article: Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study Open
Idecabtagene vicleucel (ide-cel), an adoptive chimeric antigen receptor (CAR) T-cell therapy directed against B-cell maturation antigen (BCMA), has demonstrated high response rates and improved survival in patients with relapsed/refractory…
View article: End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy Open
Background In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die from this disease or related complications. While a great amount of focus has been dedicated to the development of novel ther…
View article: The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France Open
View article: Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital Open
International audience
View article: French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry
French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry Open
Summary Idecabtagene vicleucel (ide‐cel), a chimeric antigen receptor T‐cell therapy targeting B‐cell maturation antigen (BCMA), received early access program (EAP) authorization in France in April 2021 for relapsed/refractory multiple mye…
View article: HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma Open
Despite their unprecedented success in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), anti-CD19 CAR T cells are associated with significant toxicity, and more than half of patients relapse. As monocytes emerged as key players in C…
View article: Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified Open
In this retrospective study, we report 70 cases of Epstein-Barr virus (EBV)+ diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) among 1696 DLBCL-NOS cases diagnosed between 2006 and 2019 (prevalence of 4.1%). At diagnosis, m…
View article: Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study
Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study Open
View article: Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients’ knowledge to manage adverse effects
Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients’ knowledge to manage adverse effects Open
Long-term multiple myeloma therapy by immunomodulatory drugs (IMiDs) raises the question of management of adverse effects. The aim of this study is to assess the impact of an educational session for patients on the acquisition of knowledge…
View article: Commercial <scp>anti‐CD19 CAR</scp> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Commercial <span>anti‐CD19 CAR</span> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center Open
Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). …
View article: PB2145 POMALIDOMIDE AND DEXAMETHASONE IN RELAPSING POEMS SYNDROME: A FRENCH REPORT OF 5 CASES
PB2145 POMALIDOMIDE AND DEXAMETHASONE IN RELAPSING POEMS SYNDROME: A FRENCH REPORT OF 5 CASES Open
Background: Significant improvements have been made in the management of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy and skin changes) syndrome, but patients (pts) still experience relapses or refractoriness.…
View article: MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis
MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis Open
MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis *Significant differences between the three groups: percentage of response superior to very good partial response (P=0.04…